NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 41 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $113,440 | +18.6% | 136,675 | 0.0% | 0.00% | – |
Q1 2023 | $95,673 | +37.5% | 136,675 | 0.0% | 0.00% | – |
Q4 2022 | $69,568 | -94.7% | 136,675 | -93.4% | 0.00% | -100.0% |
Q3 2022 | $1,321,000 | -10.8% | 2,064,222 | +43.6% | 0.01% | -16.7% |
Q2 2022 | $1,481,000 | -35.7% | 1,437,417 | +17.3% | 0.01% | -33.3% |
Q1 2022 | $2,303,000 | -52.7% | 1,225,000 | +21.2% | 0.01% | -52.6% |
Q4 2021 | $4,872,000 | -32.6% | 1,010,790 | +1.1% | 0.02% | -40.6% |
Q3 2021 | $7,230,000 | -11.3% | 1,000,000 | +13.2% | 0.03% | -13.5% |
Q2 2021 | $8,151,000 | -49.4% | 883,102 | -32.5% | 0.04% | -50.7% |
Q1 2021 | $16,109,000 | -4.5% | 1,308,600 | +9.4% | 0.08% | -8.5% |
Q4 2020 | $16,860,000 | +40.5% | 1,195,725 | +19.6% | 0.08% | +34.4% |
Q3 2020 | $11,996,000 | +47.2% | 999,694 | +103.6% | 0.06% | +15.1% |
Q2 2020 | $8,151,000 | +19.1% | 490,996 | -18.3% | 0.05% | -5.4% |
Q1 2020 | $6,842,000 | +338.0% | 601,193 | +374.2% | 0.06% | +600.0% |
Q4 2019 | $1,562,000 | – | 126,782 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |